Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
A phase 2 trial of Tucidinostat (chidamide) in peripheral T-cell lymphomas, run by Great Novel Therapeutics Biotech & Medicals Corporation, now recruiting.
Overview
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) is a phase 2 interventional study registered as NCT05833724 by Great Novel Therapeutics Biotech & Medicals Corporation, with 33 participants planned, started 2024-10-18 and due to reach its primary completion in 2027-06. Interventions recorded: Chidamide.
Similar pages
not linked directly; found by shared links- TrialClinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
Shares Tucidinostat (chidamide), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Shares Tucidinostat (chidamide), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialStudy to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialValemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.